Jennerex, Transgene in JX-594 deal

Jennerex Inc. (San Francisco, Calif.) granted Transgene S.A. (Euronext:TNG) exclusive rights to develop and commercialize JX-594 in Europe, the Commonwealth of Independent States and the Middle East. The partners will co-develop the recombinant vaccinia virus (TK-deletion plus GM-CSF) worldwide, with Transgene responsible for costs and clinical development in its licensed territories. The companies plan to conduct a Phase IIb/III trial in hepatocellular carcinoma (HCC) and a Phase II trial to treat colorectal cancer, but have not yet established a timeline for starting the trials. ...